Search

Your search keyword '"Moreno, Diego"' showing total 15 results
Start Over Author "Moreno, Diego" Journal foods
15 results on '"Moreno, Diego"'

2. Arazá: Eugenia stipitata Mc Vaught as a Potential Functional Food.

Author

Acosta-Vega, Luis, Moreno, Diego A., and Cuéllar Álvarez, Liceth N.

Subjects
VITAMIN C, PHENOLS, BIOACTIVE compounds, FUNCTIONAL foods, NON-communicable diseases
Abstract

Arazá is a fruit native to the Amazonian region with characteristic properties such as aroma, texture, color, and marked acidity. Additionally, the fruit is rich in bioactive compounds in its three fractions (seed, pulp, and peel), such as ascorbic acid, phenolic compounds (and their derivatives), and carotenoids, which have been extensively investigated in the literature for their beneficial properties for human health. However, it is a little-known fruit, and the role it can play in health-promoting activities related to the treatment and prevention of non-communicable diseases (NCDs) when incorporated into the diet is also unknown. Therefore, it is necessary to know the profile of bioactive compounds and the biological properties Arazá possesses, which is the aim of this review. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. The Cholesterol-Lowering Effect of Capsella Bursa-Pastoris Is Mediated via SREBP2 and HNF-1α-Regulated PCSK9 Inhibition in Obese Mice and HepG2 Cells.

Author

Hwang, Jin-Taek, Choi, Eunji, Choi, Hyo-Kyoung, Park, Jae-Ho, Chung, Min-Yu, and Moreno, Diego A.

Subjects
LIPOPROTEIN receptors, OBESITY, TRANSCRIPTION factors, MICE, LOW density lipoprotein receptors
Abstract

The objective of the present study was to investigate the mechanism by which capsella bursa-pastoris ethanol extract (CBE), containing 17.5 milligrams of icaritin per kilogram of the extract, and icaritin, mediate hypocholesterolemic activity via the low-density lipoprotein receptor (LDLR) and pro-protein convertase subtilisin/kexin type 9 (PCSK9) in obese mice and HepG2 cells. CBE significantly attenuated serum total and LDL cholesterol levels in obese mice, which was associated with significantly decreased PCSK9 gene expression. HepG2 cells were cultured using delipidated serum (DLPS), and CBE significantly reduced PCSK9 and maintained the LDLR level. CBE co-treatment with rosuvastatin attenuated statin-mediated PCSK9 expression, and further increased LDLR. The icaritin contained in CBE decreased intracellular PCSK9 and LDLR levels by suppressing transcription factors SREBP2 and HNF-1α. Icaritin also significantly suppressed the extracellular PCSK9 level, which likely contributed to post-translational stabilization of LDLR in the HepG2 cells. PCSK9 inhibition by CBE is actively attributed to icaritin, and the use of CBE and icaritin could be an alternative therapeutic approach in the treatment of hypercholesterolemia. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results